International Journal of Advanced Research in Biological Sciences
ISSN: 2348-8069
www.ijarbs.com
DOI: 10.22192/ijarbs Coden: IJARQG(USA) Volume 3, Issue 10 - 2016

Review Article

DOI: http://dx.doi.org/10.22192/ijarbs.2016.03.10.004

A clinical review on the pathology and management "*Helicobacter pylori*" infection.

Debanjan Das*[1], Muhammad Abbas[2], Md. Akabar[3], Akriti Nepal[4], Md. Ariful Islam[5] , Abdullahi Ayuba[6] , Naved Mallick[7] , Awaisullah Ihsen[8]

[1,4,5]Department of Pharmacology
[3]Department of Pharmaceutics
[6]Department of Microbiology
[2,7,8]Department of Clinical Pharmacy
China Pharmaceutical University, School of Pharmacy, Nanjing PR, China
*Corresponding author: *debanjanimagine@outlook.com*

Abstract

"*Helicobacter pylori"* have now been established as one of the sources of acute and chronic gastritis, duodenitis, gastric peptic ulcers and duodenal ulcers non-ulcer dyspepsia and Weird diseases and syndromes. It has been identified as a risk factor for gastric cancer and MALT-lymphoma. More than 90% of patients with duodenal ulcers and more than 70% of those with gastric ulcer and more than 80% patients with the gastric cancer have "" infection. Diagnosis of "" could be meddlesome like endoscopy and non-interfering such as urea-breath-test, detection of antigens in stool, detection of specific antibodies in patients' sera by means of serological tests--ELISA and Immunblott, molecular tests PCR and fluorescence-in situ- hybridization which also checks its resistance against clarithromycin and metronidazole. The treatment is still a challenge. There are many determinants for successful therapy like individual primary or secondary antibiotics resistance, mucosal drug concentration, patient compliance, side-effect profile and cost. Latest therapy relies on different mixtures of known antibiotics and anti-secretory agents. In a few studies, a standard triple therapy consisting of two antibiotics and a proton-pump inhibitor has been proposed as the first-line regimen. Bismuth-containing quadruple treatment, sequential treatment or a non-bismuth quadruple treatment (concomitant) are also an alternative therapy. Levofloxacin containing triple treatment are recommended as rescue treatment for infection of "" after defeat of first-line therapy. Achieving a successful *"H. pylori"* vaccine is a feasible route towards treatment which will have synergistic or additive consequence against "*H. pylori*".

Keywords: *H.pylori*, Peptic Ulcer, Gastritis.

Introduction

About 2 decades ago, *Helicobacter pylori* have been the main target of basic biochemical and clinical analysis and controversy since its initiation to the scientific association by Marshall and Warren. Precisely, it is unassailable to peptic ulcer disease, gastric malignancy and gastritis due to its concernment to human disease.[2] For accessing the organism, there are still many questions remained for regarding the flawless diagnostic and therapeutic regimens. The probability of progressing an efficacious vaccine adjacent to the organism which is the ongoing work centralizing on the significance of calibrating the Pylori genome.[5] A concise outline of the epidemiology and pathogenesis of ""*H. pylori*"" infection is the

main focused part of this article. Pertinent distinguishing and therapeutic approaches of characteristic clinical demonstration of ""*H. pylori*"" infection are examined.[2] The future dissolution of the structure by testing developing techniques which includes advancement of vaccines as a symbolic human pathogen which concludes our article.

A flagellum, gram negative, microaerophilic bacterium which is spiral in shape and conquers in the human gastric mucosa due to which *Helicobacter pylori* is epidemic for decades. Almost all over the world about 50-75%of the population was influenced by the utmost and the frequent bacterial infection known as "*H.pylori*".[23]Peptic ulcer disease (gastric and duodenal),chronic gastritis, gastric cancer and gastric mucosal-correlated lymphoid tissue lymphoma are the upper gastrointestinal diseases which are the main limits of "*H.pylori*".[21]"*H.pylori*" also cause chronic and low-grade inflammation in the gastric mucosa along with upper gastrointestinal problems which could point to some catabolic ataxia. There is a coordination and decreased density lipoprotein cholesterol, increased total and in affected peoples there is a decrease of high density lipoprotein. Thus, "*H. pylori*" have a demanding role in other extra gastric diseases such as chronic urticarial.[45]

For the abrogation of "*H.pylori*" for achieving another adequate resistance have been proposed despite of variety of treatment procedures. The first line treatment for "*H.pylori*" infection in the procedures in the modern years isthat it utilizes proton pump inhibitors (PPIs) in combination with few antibiotics such as amoxicillin plus clarithromycin or metronidazole.[1]Due to the immense rates of antibiotic resistance and PPI-based triple therapy which has been explained to be failing its efficacy for "*H.pylori*", its high rates of antibiotic related side effects and low compliance along with the eradication cure rates as low as 50%to70%.[4]The use of new first line treatment has been developed due to the decreased eradication rate. Due to the lack of studies of clarithromycin resistance and national validation studies, these new first line treatments are not welcomed in some of the countries.[3]

The bismuth –containing quadruple therapy is an alternative for the first line experimental treatment which was endorsed with the Maastricht IV/Florence Consensus Report in the areas with the clarithromycin counteraction over 15-20%. A nonbismuth quadruple therapy or a sequential therapy which is called concomitant treatment is approved if this process is not available.[44]As a second line treatment bismuth –containing quadruple therapy or levofloxacin –based triple therapy is approved which is also called rescue therapy which is approved after theunsuccess of PPI clarithromycin treatment for """*H. pylori*""" infection.[5]

For the patients who have penicillin allergy, the bismuth containing quadruple therapy appears to be a preferred choice than a PPI-clarithromycin metronidazole combination therapy for the first line treatment.[6]PPI along with clarithromycin are considered as a second line treatment which is known as a rescue therapy also contains levofloxacin along with in the presence of penicillin allergy.[7]

After the breakdown of second-line treatment, the use of antimicrobial susceptibility testing which is also known as culture –guided therapy has been approved by the Maastricht IV/Florence Consensus Report.[9]As, culture-guided third-line therapy has been well considered but if antimicrobial susceptibility data are not available, then an empirical triple or quadruple therapy can be approved as third line regimen.[8] There is still absence of least harmful therapeutic therapy to cure "*H.pylori*" infection in all expressed colonized individuals and during the previous 30 years as such "*H.pylori*" was identified in which there have been various therapeutic procedures suggested.[11]

Epidemiology

For any risky circumstances, its mode of communication and numinous researches has tried to determine the frequency and pervasiveness of "*H.pylori*" infection.[10] It was in between 0.3% and 0.5% per year in the advanced countries which was the yearly proportion rate recorded in 3 grown up studies.[18] Confiding on tendency of the native study and the area of the review class, 2-4 pervasiveness evaluates vary greatly.[20]

Notably in advanced countries, in regular condition, pervasiveness rises with age and then it associates firmly with an inferior economic condition during childhood globally as the "*H.pylori*" infection is decreasing. [17]A fecal-oral or oral-oral route mostly in the timing of childhood, there is the procurement of "*H.pylori*". An appearance for a gastro oral route has also designed some studies of transmission.[19] There are various studies been carried out mainly, genetic predilection to infection, alcohol and tobacco use, ABO blood type and dietary &nutritional influences which were the role played by other reasons and its results have been illogical.[16] A comprehensive

pervasive of infection of almost 40% which was surprisingly a latter survey of 655 topics from a teaching hospital in Rome with an increased pervasiveness among nurses and complementary apprentices than among the physicians.[15]

PATHOGENESIS

Pathogenicity and Virulence Factors

The recent category of organisms classified it primarily extracellular, gram-negative, and flagellated and motile in **Figure 1**.



Figure 1. Photomicrograph of *Helicobacter pylori*

With the rapid development of biochemical techniques, new studies of pathogenicity and virulence factors of "*H. pylori*" has forth come, in addition the infection course by "*H.pylori*" need a complex interaction of both bacterial and host factors.[14]Reseachhas identified several bacterial proteins necessary for colonization of the gastric mucosa by "*H.pylori*", including proteins active in the transport of the organism to the surface of the mucosa (e.g., flagellin, which is encoded on genes flaA and flaB).[19] Once in the presence of the gastric mucosa, bacteria induce a transient hypochlorhydria by an unknown mechanism.[13] The urease enzyme produced by the bacteria alters the microenvironment of the organism to facilitate colonization. Adherence then occurs via interaction between cell-surface glycolipids and adhesions specific to "*H.pylori*".[16] There also appears to be a role played by proteins called cecropins, which are produced by "*H.pylori*" and inhibit the growth of competing organisms, as well as by a P-type adenosinetriphosphatase, which helps prevent excessive alkalinization of the microenvironment by urease. Once attached to gastric mucosa, "*H.pylori*" causes tissue injury by a complex cascade of events that depends on both the organism and the host. "*H.pylori*", like all gram negative bacteria, have in its cell wall lipopolysaccharide, which acts to disrupt mucosal integrity. Furthermore, "*H.pylori*" secrete several pathogenic proteins that cause cell injury.[34] For example, the CagA protein, release by cytotoxic-associated gene A (cagA), is a highly immunogenic protein that may be partner with more severe clinical syndromes, such as duodenal ulcer, gastric adenocarcinoma. Therefore there is increasing facts that CagA positivity is associated with an increased risk factor for distal, but not nearness, gastric adenocarcinoma. Hence, protein products of the vacuolatingcytotoxin A gene (vacA) and the A gene lead by contact with epithelium (iceA) are known to be partner with mucosal injury.[32] In addition When colonization of the gastric mucosa has taken place, the immunogenic properties of "*H.pylori*" cause an inflammatory reaction with neutrophilic gastritis that eventually results in the clinical manifestations of the occurrence of infections shown in **Figure 2**.



Figure 2. Photomicrograph showing type B neutrophilic gastritis

This process is also mediated by host factors, including interleukins 1, 2, 6, 8, and 12; interferon Gamma; tumor necrosis alpha factor i.e. T and B lymphocytes; and phagocytic cells.31 These factor causes injury through release of reactive oxygen species and inflammatory cytokines. "*H.pylori*" furthermore it appears to increase the rate of mucosal programmed cell death (also known as apoptosis).[36]These patients may likely tend to have a milder phenotypic expression of the gastritis, with irritate mostly in the antrum or distal part of the stomach. In contrast, most of the patients with gastric adenocarcinoma,a known complication of "*H.pylori*" infection, may likely tend to have pangastritis, with the involvement of the acid-secreting body of the stomach as well as the antrum.[30] This situation leads to atrophy of parietal cells (which are responsible for producing acid) and gastrin-producing cells of the antrum and eventually produces achlorhydria. Patients with gastric adenocarcinoma also have impaired acid secretion in response to stimulation with gastrin.[29]

Pathologic Findings

Even extensive studies were carrying out to identify histopathologic changes seen with "*H.pylori*" infection.[22] After colonization, most appears to be an intense neutrophilic infiltrate in the tapered of the mucosal glands. Epithelial changes are usually common when there is irregularity of the receptor architecture, in which improper use of atrophy of glands is typical of longstanding infection.[21] Furthermore, there is usually lymphocytic infiltration in the stroma and impaired mucus excretion. Finally, areas of patches intestinal metaplasia may be seen, which are pivotal to the growth of neoplasia.[20]

Effects on Gastric Physiology

Hence, this help in producing injury of gastric mucosa, "*H.pylori*" castrate the normal gastric secretion. Furthermore, the location and severity of the infection.[37] Likely to be close in associated with the ultimate clinical outcome, most seem to be effects on gastric physiology. Many researches have indicated that patients with a duodenal ulcer who are infected with "*H.pylori*" have an increased serum level of gastrin, which in turn leads to increased.[38]

CLINICAL MANIFESTATIONS AB

Gastritis and Gastric Cancer

Once infected with "*H.pylori*", the majority of persons remain asymptomatic. Some persons recover the infection, with seroreversion rates usually account in the assortment of 5% to 10%; it is not identified if this seroreversion is fallout from abolition of the organism by antibiotic agents used to treat other symptoms.[40]

However, the typical course of infection in patients begins with chronic superficial gastritis, in due course it progress to atrophic gastritis.[39] This progression becomes visible to be a main episode in the cellular cascade that consequences gastric carcinoma. Record points out a 90-fold raise in patient number have gastric carcinoma with severe, multifocal atrophic gastritis, compared with standard controls.[39]

The mechanism of tumorigenesis appears to engross DNA damage tempted by different cytokines and free radicals out in the situation of chronic inflammation in vulnerable persons.[38] Although "*H.pylori*" is linked with the increase growth of adenocarcinoma of the antrum and body of the stomach and it is undoubtedly linked with gastric mucosa–related lymphoid tissue (MALT) lymphomas.[43] "*H.pylori*" kindle lymphocytic infiltration of the mucosal stroma; this infiltration may possibly act as a focus for cellular changes and proliferation, finally resulting in neoplastic conversion to lymphoma.[22]It proves that "*H.pylori*" also produce proteins that increase the growth of lymphocytes in the early stages of neoplasia. Most expressively, it has been recorded that deterioration of low-grade gastric MALT lymphoma can be attained in 70% to 90% of patients with suppression of "*H.pylori*"infection.[13]

Current work has publicized that endoscopic ultrasound examination to be very useful in identifying the grade of MALT lymphoma and in envisaging the effectiveness of treating the "*H.pylori*" infection to obtain degeneration of the lymphoma.[40]

Peptic Ulcer Disease

The liaison between "*H.pylori*" infection and peptic ulcer disease has been studied comprehensively, and it is now documented that the organism is the main cause of peptic ulcer disease worldwide.[42]Exterminating the infection can modify the naturalcourse of peptic ulcer disease by

spectacularly dropping the rate of its reappearance in treated patients, compared with untreated patients.[41]

This diminution takes place in patients with duodenal and gastric ulcers who have no record of non steroidal anti-inflammatory (NSAID) drug use.[45] The mechanism by which "*H.pylori*" causes' peptic ulcer disease is partly understood but probably it involves a combination of genetic tendency of the host, virulence aspects of the organism (eg, VacA and CagA proteins), mechanical damage to the mucosa, and changes of gastric and duodenal secretions.

Nonulcer Dyspepsia

Nonulcer dyspepsia is a group of varied indication, counting dysmotility-like, ulcer-like, and reflux-like indications.[44] Many possible causes have been noted for nonulcer dyspepsia, together with lifestyle factors, stress, distorted visceral sensation, and bigger serotonin sensitivity, variations in gastric acid secretion and gastric emptying, and "*H.pylori*" infection.[8]

A recent appraisal also explained the role of psychosocial impairment (e.g. depression, somatization, anxiety) in patients with nonulcer dyspepsia.[45]In a study relating "*H. pylori*" infection to nonulcer dyspepsia, patients with the latter condition were twice as expected to be positive for the organism.

However, even with such epidemiologic facts, treatment studies have botched to consistently show that removal of "*H.pylori*" consequences in improvement of nonulcer dyspepsia indications.

Consequently, eradication of the "*H.pylori*" organism cannot be considered the normal standard of care in all patients with nonulcer dyspepsia, for the reason that "*H.pylori*" infection is only a single component of the mutifactorial etiology of the disease.[43]

Gastroesophageal Reflux Disease

Much consideration has been focused on the potential relationship between infection with "*H.pylori*" and gastroesophageal reflux disease (GERD) in its various indications (e.g. esophagitis, Barrett's esophagus).[48] Some investigators have suggested a relationship between the existence of "*H.pylori*" and a less risk for developing esophagitis and Barrett's esophagus. Although this contrary connection is supported by many prevalence studies, others not succeed to show it.[54]

Studies have also specified that certain strains of "*H.pylori*", especially the CagA positive strain, may be protective next to the development of Barrett's esophagus. Furthermore, Labenz and colleagues have exposed that the prevalence of esophagitis may, in fact, rise after eradication of the organism.[49]Treatment of "*H.pylori*" infection can be able to lead to exacerbation of GERD in lots of patients, prompting many gastroenterologists to defer endoscopic antral biopsies in patients having significant GERD and absent ulcer.[50]

Further studies via endoscopic findings, pH probe measurements, and histology to verify the presence of "*H.pylori*" did not find any connection between GERD and infection with "*H.pylori*". Undoubtedly, more classic studies are needed to define the relationship, if any, between these 2 entities.[52]

Other Disease Associations

Investigators have further hypothesized a relationship between "*H.pylori*" infection and cardiovascular disease

Table 1. Helicobacter pylori–Associated Conditions

Association is accepted

I. Gastric adenocarcinoma
II. Gastric mucosa–associated lymphoid tissue lymphoma
III. Gastritis
IV. Peptic ulcer disease

Association is controversial

I. Cardiovascular disease
II. Gastroesophageal reflux disease
III. Iron deficiency anemia
IV. Nonulcer dyspepsia
V. Iron-deficiency anemia.

These relationships, however, need much more study before a causal relation is established. **Table 1** reviews the disorders that have been associated with "*H.Pylori*"infection.[34]

Diagnostic Testing

Time gone science is improving day by day that's why presently so many methods are available for detecting *""H.pylori""*. Each test is different from each other.

Basically, the tests existing for analysis can be removed.[53]

According to endoscopic biopsy is necessary or not. Histologic evaluation, culture, polymerase chain reaction (PCR), and rapid urease tests are typically performed on tissue obtained at endoscopy. Not only that some other test like simple breath tests, serology, and stool assays are sometimes used, and trials investigating PCR amplification of saliva, feces, and dental plaque to detect the presence of "*H.pylori*" are ongoing.[26]

Histology

Histologic appraisal has usually been the gold standard method for identifying "*H.pylori*" contagion. The disadvantage of this technique is the need for endoscopy to obtain tissue. Restrictions also arise at times because of an incompetent number of biopsy specimens obtained or failure to obtain specimens from distinct areas of the stomach. In some cases, different staining techniques may be necessary, which can involve longer processing times and higher costs.[56] However, histologic testing does allow for definitive diagnosis of infection, as well as of the degree of inflammation or metaplasia and the presence/absence of MALT lymphoma or other gastric cancers in high-risk patients.[57]

Culture

Because "*H.pylori*" are difficult to grow on culture media, the role of culture in diagnosis of the infection is limited mostly to research and epidemiologic considerations. Although exorbitant, time-consuming, and labor-intensive, background does have a role in antibiotic susceptibility studies and studies of growth factors and absorption.[44]However, in the developed countries; culture should not be considered a routine, first-line means of diagnosis.[58]

Polymerase Chain Reaction

With the advent of PCR, many exciting possibilities emerged for diagnosing and classifying "*H.pylori*" infection.PCR allows identification of the organism in small samples with few bacteria present and entails no special requirements in processing and transport. Moreover, PCR can be performed rapidly and cost-effectively, andit can be used to identify different strains of bacteria for pathogenic and epidemiologic studies. As suggested earlier, PCR also is being evaluated for its utility in identifying "*H.pylori*" in samples of dental plaque, saliva, and other easily sampled tissues. The major control of PCR is that relatively few laboratories currently have the capability to run theassay.[3] In addition, because PCR can detect segments of "*H.pylori*" DNA in the gastric mucosa of previously treated patients, false-positive results can occur, and errors in human interpretation of bands on electrophoretic gels can similarly lead to false-negative results.[12]

Rapid Urease Testing

Rapid urease testing takes advantage of the fact that "*H.pylori*" is a urease-producing organism. Samples obtained on endoscopy are placed in urea-containing medium; if urease is present, the urea will be broken down to carbon dioxide and ammonia, with a subsequent increase in the pH of the medium and a subsequent color change in the pH-dependent indicator. This test has the advantages of being inexpensive, fast, and widelyavailable.[43] It is limited, however, by the possibility of false positive results; decreased urease activity, caused either by recent ingestion of antibiotic agents, bismuth compounds and proton pump inhibitors or sucralfate or by bilereflux, can contribute to these false-positive results.[47]

Urea Breath Test

A urea breath test similarly relies on the urease activity of "*H.Pylori*" to detect the presence of active infection. Inthis test, a patient with suspected infection ingests either14C- categorized or 13C- labeled urea; 13C- labeled urea has the advantage of being nonradioactive and thus safer for children and women of childbearing age.[54]

Urease, if present, splits the urea into ammonia and isotope-labeled carbon dioxide; the carbon dioxide is absorbed and eventually expired in the breath, where it is detected. Besides being excellent for documenting active septicity, this test is also valuable for establishing absence of infection after treatment, an important consideration in patients with a history of complicated ulcer disease with bleeding or perforation. In addition, a urea breath testis relatively inexpensive and easy to perform, and does not require endoscopy.[21]Nevertheless, if the patient has recently sipped proton pump inhibitors, antibiotic agents, a urea breath test can be of limited value. Therefore, at least 1 week should separate the discontinuing of antisecretory medications and testing for active infection and 4 weeks should separate treatment of

"*H.pylori*" infection and testing for eradication of the organism. Moreover, except for major medical centers or tertiary referral centers where results are usually available in fewer than 24 hours, a urea breath test may be further limited by a turnaround time of several days required for transport of samples and analysis by specialized laboratories not present in many communitysettings.[41]

Serologic Tests

In reaction to "*H. pylori*" infection, the immune systemtypically mounts a response through production of immunoglobulins to organism-specific antigens. These antibodies can be detected in serum or whole-blood samples easily obtained in a physician's office. The presence of IgG antibodies to "*H.pylori*" can be detected by use of a biochemical assay, and many different ones are available. Serologic tests offer a fast, easy, and relatively inexpensive means of identifying patients who have been infected with the organism.[9] However, this method is nota useful means of confirming eradication of "*H.pylori*"; several different samples and changes in titers of specified amounts over time would be needed. In addition, few patients become truly sera negative, even after eradication of the organism. In low-prevalence populations, serologic tests should be a second-line methodology because of low positive predictive value and a tendency toward false-positive results. Serologic tests may be useful in identifying certain strains of more virulent "*H.pylori*" by detecting antibodies to virulence factors associated with more severe disease and complicated ulcers, gastric cancer, and lymphoma.[15]

Stool Antigen Testing

Stool antigen testing is a relatively new methodology that uses an enzyme immunoassay to detect the presence of "*H.pylori*" antigen in stool specimens. A cost effective and reliable means of diagnosing active infection and confirming cure, such testing has a sensitivity and specificity comparable to those of other non invasive tests.[53]Questions remain regarding possible cross reactivity with other Helicobacter species existent in the guts, but definitive studies are lacking.[58]

General Diagnostic Principles

The question of which patients to test, when to test them, and what test to use is still a troubling one for many physicians. Ultimately, the answer to these questions must be based on patient preference, cost, Availability of different tests, and positive and negative predictive values of different tests. Nevertheless, certain principles of testing seem universal. First, endoscopic methods of diagnosis should be used only if the procedure is necessary to detect some other condition besides "*H.pylori*" infection. Second, only those patients in whom treatment will make a difference should be tested.[19] Definite evidence does not exist that eradication of the infection in patients with simple dyspepsia will relieve symptoms and testing of asymptomatic patients without a history of documented peptic ulcer disease is not warranted. Testing can be considered on a case by case basis in patients with symptoms suggestive of peptic ulcer disease. Because treatment of "*H.pylori*" infection is definitely indicated in patients with active or previously documented peptic ulcer disease, gastric MALT lymphoma, or family history of gastric cancer, their "*H.pylori*" status must be clarified. Urea breath and stool antigen tests are the most cost-efficient tests to identify active infection, but their confines must be considered. Although serology is an excellent, inexpensive test to ascertain if someone with a history of peptic ulcer disease and unknown "*H.pylori*" status warrants treatment, endoscopy with tissue sampling in patients with a history of peptic ulcer disease can provide more definitive diagnosis of "*H.pylori*" infection, as well as information about the activity of peptic ulcer disease and possibly other factors at play (including gastric carcinoma).Follow-up testing with urea breath or stool antigen tests is necessary to document cure in patients with complicated peptic ulcer disease (like perforation, hemorrhage, obstruction) or recurrent symptoms and should be performed 4 weeks after completion of treatment.[33]

MANAGEMENT

General Treatment Principles

Determining the optimum treatment of "*H.pylori*" infection is difficult, because the organism lives in an environment not easily accessible to many medications and because emerging bacterial resistance presents an added challenge.[19] Moreover, many of the recommended regimens are difficult for patients to take, leading to problems with compliance; specifically, having to take a large number of pills at least twice daily and coping with unpleasant adverse effects do little to encourage patient cooperation. Despite these obstacles, current regimens can obtain cure rates in excess of 85% in most patient populations.[21]

Cure of "*H.pylori*" infection

Cure of "*H.pylori*" infection by finding the best possible therapy is complex due to the presence of organism in such an atmosphere that several medications cannot easily reached there and rising bacterial resistance show new threat. Furthermore, Patients feel uncomfortable to take the recommended regimens due to numerous amount of medicine have to take two times on every day and disagreeable side effects discourage patient support and compliance. Regardless of these barriers, Present drug therapy is able to treat more than 85% of total patients.[39]

Antibiotic Agents

Currently, antibiotic agents used to treat "*H.pylori*" infection are administered in combination, with no single agent ever used as monotherapy because of a lack of efficacy and the potential development of resistance. Metronidazole has activity independent of pH, but resistance to the drug is common in the United States.[46] This problem with resistance is ameliorated somewhat, however, when the drug is used with clarithromycin. Metronidazole can have unpleasant adverse effects (e.g. nausea), and a disulfiram-like reaction to alcohol ingestion is possible, although exceedingly rare.[36] Clarithromycin has lower rates of resistance (approximately 7%–11%) 62 but is not acid stable, may cause dysgeusia, and is more expensive than other antibiotic agents. Resistance to amoxicillin is rare, but this drug usually requires the co administration of a proton pump inhibitor because its activity is pH-dependent. Finally, tetracycline has the advantage of low cost and low occurrence of resistance but can cause discoloration of the teeth in children and photosensitivity reactions.[21]

Presently, antibiotic drugs had given to patients to cure "*H.pylori*" infection in combination with other drugs because monotherapy has less effectiveness and possible chance for growth of resistance. The function of Metronidazole does not depend on pH. However; resistance to this drug is widespread in United States. The trouble of drug resistance can improve by taking this medicine with Clarithromycin.[28] Distasteful side effects (e.g.nausea), and disulfiram –like reaction to alcohol intake is likely when Metronidazole is consume. Though, it is extremely unusual. Clarithromycin is most costly as compare to other antibiotic drugs but it has less degree for resistance (around 7%-11%) 62.However, this drug is acid sensitive and might induce dysgeusia. The action of amoxicillin is relying on pH. Hence, this antibiotic generally needs to take simultaneously with proton pump inhibitor and resistance to this drug is unusual. At last, tetracycline has benefit of fewer prices and less chance for resistant development however it might make discoloration of children's teeth and induce photosensitivity reactions. [58]

Adjunctive Agents

The most popular agents currently used in combination with antibiotic agents to eradicate "*H.pylori*" infection are the proton pump inhibitors, with omeprazolebeing the most widely studied drug. Omeprazole acts not only by directly inhibiting bacterial microsomal enzymes but also by raising intragastric pH, thus facilitating the action of antibiotic agents, reducing gastric secretions, and increasing antibiotic concentrations in the stomach. Other adjunctive agents include histamine receptor antagonists and ranitidine bismuth citrate, which has antisecretory properties in addition to the antibacterial action of bismuth (ie, interruption of the bacterial cell wall). However, ranitidine bismuth citrate is no longer available in the United States.[11]

Presently, the antibiotic drugs are administered together with mainly proton pump inhibitors to treat "*H.pylori*" infection. While, investigation on omeprazole is more as compare to other drugs. Omeprazole perform its action through suppression of bacterial microsomal enzymes as well via increasing intragastric pH. Hence, decreasing gastric secretions and raising antibiotic amounts in the stomach.[29] So, in this way, it promotes the function of antibiotic drugs. Histamine receptor antagonists and ranitidine bismuth citrate are additional adjunctive agents. Both have antisecretory function while bismuth has also antibiotic function (i.e.interruption of the bacterial cell wall).Though, Ranitidine bismuth citrate is not finding in the United States after long time.

Current Regimens

Presently in the United States, the most efficacious regimens include 2 antibiotic agents and at least 1 adjunctive agent for 14 days.63 A European study hasclaimed adequate cure rates with a 7-day course of quadruple therapy (2 antibiotics, 2 adjunctive agents), but other studies have not confirmed this finding.[32]

Most clinicians treat "*H.pylori*" infection with a triple drug or even quadruple-drug approach. The 1998 guidelines from the American College of Gastroenterology61 judged the following3 regimens

to be optimal:

I. Administration of a proton pump inhibitor, clarithromycin, and either metronidazole or amoxicillin for 2 weeks;
II. Administration of ranitidine bismuth citrate (this guideline preceded the drug's withdrawal in the United States), clarithromycin, and either metronidazole, amoxicillin, or tetracycline for 2 weeks;
III. Protons pump inhibitor, bismuth, metronidazole, and tetracycline for 2 weeks. More recent recommendations outlined in a postgraduate course offered by the American Gastroenterology Association propose the use of newer proton pump inhibitors.

For patients who fail initial triple-drug therapy, according to follow-up testing, subsequent therapy should involve using a different combination of available antibiotic agents, increasing the duration of treatment, or incorporating a course of quadruple therapy. Culture with sensitivity testing should be performed after 2 treatment failures.[28]

Two antibiotic agent and minimum one adjunctive agents for 14 days.63 is the best effective regimens presently in United States. According to European investigation, quadruple therapy (two antibiotics and two adjunctive agents) for 7 day has satisfactory treatment result. Although, this result was not proved by other investigation.[31]

All most all physicians used a triple drug or even quadruple-drug plan to cure "*H.pylori*" infection. The American College of Gastroenterology provides the 1998 guiding principle which evaluates the potential ability of these three regimens.

I. Giving a proton pump inhibitors, clarithromycin and either metronidazole or amoxicillin for two weeks.
II. Giving of ranitidine bismuth citrate (this guiding principle came before the removal of medicine from United States), clarithromycin, and either metronidazole, amoxicillin or tetracycline for two weeks.
III. A proton pump inhibitor, bismuth, metronidazole and tetracycline for two weeks. The American Gastroenterology Association presented most current proposal guidelines in a postgraduate syllabus which suggest focusing on application of recent proton pump inhibitors. A patient in which initial triple therapy was not responding, then successive therapy must include by mixing different kind of existing antibiotic drugs, rising the time required for healing or include quadruple therapy plan after follow-up checking. If two treatments was not success, then culture with sensitivity testing must be done.[53]

EMERGING THERAPIES

Antibiotics and Other Agents

The medicine resistance of developing remains to eliminate "*H.pylori*" infection to epidemic efforts, incorporating existing on the new therapeutic regimens of newly developed compounds is essential and antibiotic agents. Omeprazole mixture has been assured as an active agent through Nitazoxanide.[19]And additional surveillance is continuing. In accumulation, the clarithromycin might show a character of imminent therapies except macrolides. "*H.pylori*" are opened the new path in arena of the planning of the comprehensive genome for chemotherapeutic drugs. Performance on the particular significant protein produces animated to subsistence of the bacterium that will now be potential to advance mediators.[25]

Vaccine

Urea catalyzed the hydrolysis is urease encouraging about gastric "*H.pylori*" species. The bacteriological persistence and annexation and consumes precise durable antigenicity then are the acute in acidic disorder of the intestinal of UreB are the preserve urease action unit. The bacteriological colonization in acid is vital reason for stomach of UreI, an "*H.pylori*"urea passage protein. In an investigation, two antigenic remains (UreB and UreI) of "*H.pylori*" and cholera toxin B subunit (CTB), a multi-epitope vaccine intended too much defense properties of "*H.pylori*" experiment around BALB/c mice and multi-epitope antigen is both intramuscular injection and oral administration of UreI and UreB with CTB had resistant protecting outcome beside "*H.pylori*" experiment, the advanced contamination safety proportion of "*H.pylori*" is oral administration. In additional, admin requirements to remain distinct from the ideal route such as nasal and rectal routes with studies in mice indication potential, the probable causes would avoid of postimmunization gastritis likely with an oral route.[43]

In the global, the bacterium is liable for substantial disease and death, and is widespread, and of eradicate to makes it a prime target for vaccine therapy is difficult and expensive. The vaccination against "*H.pylori*" septicity remained potential, centered arranged murine reproductions is innovative exertion that providing indication in the initial 1990s. The bacterium ensued via incentive of T-helper type 2 phenotype cells, that the significant mechanism of defensive resistance not to by antibody invention is convinced by the invention of interleukins 4 and 10.

Numerous other "*H.pylori*" proteins require previously remained described as active vaccine antigens such as cytotoxin associated gene A, vacuolating cytotoxin A (Vac A) neutrophil-activating protein heat-shock proteins surface-localized protein HpaA. Effectiveness of vaccination with recombinant HpaA from *Helicobacter pylori* is influenced by host genetic background.[40] These are possible a permutation with each other of particular stated antigens or through a proper adjuvant might encourage a protecting consequence over vaccination. Effectiveness of vaccination with recombinant HpaA from *Helicobacter pylori* is influenced by host genetic background. A truncated form of HpaA is a promising antigen for use in a vaccine against *Helicobacter pylori*. Through the years beneficial antibodies existing appreciated tools of affecting an extensive range of enteric diseases and pathogens with the Significant reduce intragastric "*H.pylori*" density of humans that have shown monotherapy with bovine antibody based oral immunotherapy is well tolerated. The produce durable T and B cell resistant reactions would stay by way of a beneficial for the enlargement vaccines of virus-like particles and nano beads by an exterior adsorbed antigen.[9]

In addition , to make sure complete sterilization of the gastric mucosa with different regimens needs to developed that the latter step have not generally been attempted to murine models , can get answer these and other questions with clinical trials .[37]

Conclusion

As the first-line treatments might stay applicable to the practice of antibiotics that is studies of the provincial certain centered on country-wide antimicrobial resistance. Suppression of "*H.pylori*" would be precious expansion of enlargement of substitute antibiotics; these potentially stimulating fragments of humans it take numerals of years formerly to investigation. Probiotic mentioned adjuvant treatment payable to immunomodulation, annexation and persistence of *H.Pylori* of stimulus of mucin invention and inhibition. In other, the investigational segment is stagnant with medicinal plants, Photodynamic therapy and vaccine as prospective possibility.

References

1. Lv ZF, Wang FC, Zheng HL, Wang B, Xie Y, Zhou XJ, Lv NH. Meta-analysis: is combination of tetracycline and amoxicillin suitable for *Helicobacter pylori* infection? World J Gastroenterol2015; 21: 2522-2533 [PMID: 25741163 DOI: 10.3748/wjg.v21.i8.2522]
2. Hajimahmoodi M, Shams-Ardakani M, Saniee P, Siavoshi F, Mehrabani M, Hosseinzadeh H, Foroumadi P, Safavi M, Khanavi M, Akbarzadeh T, Shafiee A, Foroumadi A. In vitro antibacterial activity of some Iranian medicinal plant extracts against *Helicobacter pylori.* Nat Prod Res 2011; 25: 1059-1066 [PMID: 21726128 DOI: 10.1080/14786419.2010.501763]
3. Buzás GM. Metabolic consequences of *Helicobacter pylori* infection and eradication. World J Gastroenterol2014; 20: 5226-5234 [PMID: 24833852 DOI: 10.3748/wjg.v20.i18.5226] Gu H, Li L, Gu M, Zhang G. Association between *Helicobacter pylori* Infection and Chronic Urticaria: A Meta-Analysis. GastroenterolRes Pract2015; 2015: 486974 [PMID: 25861258 DOI: 10.1155/2015/486974]
4. Ben Chaabane N, Al-Adhba HS. Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for *Helicobacter pylori* eradication: A randomized trial. Indian J Gastroenterol2015; 34: 68-72 [PMID: 25721770]
5. Olokoba AB, Obateru OA, Bojuwoye MO. *Helicobacter pylori* eradication therapy: A review of current trends. Niger Med J 2013; 54: 1-4 [PMID: 23661891 DOI: 10.4103/0300-1652.108884]
6. Dos Santos AA, Carvalho AA. Pharmacological therapy used in the elimination of *Helicobacter pylori* infection: a review. World JGastroenterol2015; 21: 139-154 [PMID: 25574087 DOI: 10.3748/ wjg.v21.i1.139]
7. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of *Helicobacter pylori* infection—the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]

8. Yang JC, Lu CW, Lin CJ. Treatment of *Helicobacter pylori* infection: current status and future concepts. World J Gastroenterol2014; 20: 5283-5293 [PMID: 24833858 DOI: 10.3748/wjg.v20. i18.5283]
9. Gisbert JP, Romano M, Gravina AG, Solís-Muñoz P, Bermejo F, Molina-Infante J, Castro-Fernández M, Ortuño J, Lucendo AJ,Herranz M, Modolell I, Del Castillo F, Gómez J, Barrio J, Velayos B, Gómez B, Domínguez JL, Miranda A, Martorano M, Algaba A,Pabón M, Angueira T, Fernández-Salazar L, Federico A, Marín AC, McNicholl AG. *Helicobacter pylori* second-line rescue therapywith levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther2015; 41: 768-775 [PMID: 25703120 DOI: 10.1111/apt.13128]
10. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311–5.
11. Parsonnet J, Blaser MJ, Perez-Perez GI, et al. Symptoms and risk factors of *Helicobacter pylori* infection in a cohort of epidemiologists. Gastroenterolgy1992;102:41–6.
12. Cullen DJ, Collins BJ, Christiansen KJ, et al. When is *Helicobacter pylori* infection acquired? Gut 1993;34:1681–2.
13. Sipponen P, Kosunen TU, Samloff IM, et al. Rate of *Helicobacter pylori* acquisition among Finnish adults: a fifteen year follow-up. Scand J Gastroenterol1996;31:229–32.
14. Malaty HM, Evans DG, Evans DJ Jr, Graham DY. *Helicobacter pylori* in Hispanics: comparison with blacks and whites of similar age and socioeconomic class. Gastroenterology 1992;103:813–6.
15. Malaty HM, Graham DY. Importance of childhood socioeconomic status on the current prevalence of *Helicobacter pylori* infection. Gut 1994;35:742–5.
16. Kosunen TU, Aromaa A, Knekt P, et al. Helicobacter antibodies in 1973 and 1994 in the adult population of Vammala, Finland. Epidemiol Infect 1997;119:29–34.
17. Stone MA. Transmission of Helicobacter pylori. Postgrad Med J 1999;75:198–200.
18. Everhart JE. Recent developments in the epidemiology of *Helicobacter pylori*. Gastroenterol Clin N Amer 2000; 29:559–78.
19. Gasbarrini A, Anti M, Franceschi F, et al. Prevalence of and risk factors for *Helicobacter pylori* infection among healthcare workers at a teaching hospital in Rome: the Catholic University Epidemiological Study. Eur J GastroenterolHepatol2001;13:185–9.
20. Eaton KA, Suerbaum S, Josenhans C, Krakowka S. Colonization of gnotobiotic piglets *by Helicobacter pylori* deficient in two flagellin genes. Infect Immun 1996;64:2445–8.
21. Rektorschek M, Weeks D, Sachs G, Melchers K. Influence of pH on metabolism and urease activity of *Helicobacter pylori*. Gastroenterology 1998;115:628–41.
22. Segal ED, Falkow S, Tompkins LS. *Helicobacter pylori* attachment to gastric cells induces cytoskeletal rearrangements and tyrosine phosphorylation of host cell proteins. Proc Natl AcadSci USA 1996;93:1259–64.
23. Putsep K, Branden CI, Boman HG, NomarkS. Antibacterial peptide from "*H.pylori*". Nature 1999;398:671–2.
24. Meichers K, Weitznegger T, Steinhilber W, et al. A novel P type ATPase cloned from *Helicobacter pylori* [abstract]. Gastroenterology 1995;108:A165.
25. Moran AP. The role of lipopolysaccharide in *Helicobacter pylori* pathogenesis. Aliment Pharmacol Ther 1996;10Suppl 1:39–50.
26. Censini S, Lange C, Xiang Z, et al. Cag, a pathogenicity island of *Helicobacter pylori*, encodes type I-specific anddisease-associated virulence factors. Proc Natl AcadSciUSA 1996;93:14648–53.
27. Graham DY, Yamaoka Y. Disease-specific *Helicobacter pylori* virulence factors: the unfulfilled promise. Helicobacter 2000;5 Suppl1:S3–9, discussion S27–31.
28. Wu A, Crabtree J, Bernstein L, et al. Role of *Helicobacter pylori* Cag A+ strains and risk of adenocarcinoma of the stomach and esophagus [abstract]. Gastroenterology 2001;120:A14.
29. Cover TL. The vacuolating cytotoxin of Helicobacter pylori.MolMicrobiol1996;20:241–6.
30. Peek RM Jr, Thompson SA, Donahue JP, et al. Adherence to gastric epithelial cells induces expression of a *Helicobacter pylori* gene, iceA, that is associated with clinical outcome. Proc Assoc Amer Physicians 1998;110:531–44.

31. Go MF, Crowe SE. Virulence and pathogenicity of *Helicobacter pylori*. Gastroenterol Clin N Amer 2000;29:649–70.
32. Vorobjova T, Maaroos HI, Sipponen P, et al. Apoptosis indifferent compartments of antrum and corpus mucosain chronic *Helicobacter pylori* gastritis. An 18-year followup study. Scand J Gastroenterol2001; 36:136–43.
33. Peterson WL, Barnett CC, Evans DJ Jr, et al. Acid secretionand serum gastrin in normal subjects and patients with duodenal ulcer disease: the role of *Helicobacter pylori.* Amer J Gastroenterol 1993; 88:2038–43.
34. Schultze V, Hackelsberger A, Gunther T, et al. Differing patterns of *Helicobacter pylori* gastritis in patients with duodenal, prepyloric, and gastric ulcer disease. Scand J Gastroenterol1998;33:137–42.
35. El-Omar EM, Oien K, El-Nujumi A, et al. *Helicobacter pylori* infection and chronic gastric acid hyposecretion. Gastroenterology 1997;113:15–24.
36. Price AB. The Sydney System: histological division. J GastroenterolHepatol1991;6:209–22.
37. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J SurgPathol1996;20:1161–81.
38. Warren JR. Gastric pathology associated with *Helicobacter pylori*. Gastroenterol Clin N Amer2000;29:705–51.
39. Sipponen P, Kekki M, Haapakoski J, et al. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. Int J Cancer 1985; 35:173–7.
40. Scheiman JM, Cutler AF. *Helicobacter pylori* and gastriccancer. Amer J Med 1999;106:222–6.
41. Parsonnet J, Hansen S, Rodriguez L, et al. *Helicobacter pylori* infection and gastric lymphoma. N Engl J Med1994;330:1267–71.
42. Zucca E, Bertoni F, Roggero E, et al. Molecular analysis ofthe progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N Engl J Med 1998; 338:804–10.
43. Morgner A, Bayerdorffer E, Neubauer A, Stolte M.Gastric mucosa-associated lymphoid tissue lymphoma and *Helicobacter pylori*. Gastroenterol Clin North Am

Nakamura S, Matsumoto T, Suekane H, et al. Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of *Helicobacter pylori.* Gut 2001; 48:454–60.

44. Van der Hulst RW, Rauws EA, Koycu B, et al. Prevention of ulcer recurrence after eradication of *Helicobacter pylori*: a prospective long- term follow-up study. Gastroenterology1997;113:1082–6.
45. Cohen H. Peptic ulcer and *Helicobacter pylori*. Gastroenterol Clin North Am 2000;29:775–89.
46. Olden KW, Drossman DA. Psychologic and psychiatric aspects of gastrointestinal disease. Med Clin North Am2000; 84:1313–27.
47. Armstrong D. *Helicobacter pylori* infection and dyspepsia. Scand J Gastroenterol Suppl 1996; 215:38–47.
48. Talley NJ, Vakil N, Ballard ED 2nd, Fennerty MB. Absence of benefit of eradicating *Helicobacter pylori* in patients with nonulcer dyspepsia. N Engl J Med 1999;341:1106–11.
49. Loffeld RJ, Werdmuller BF, Kuster JG, et al. Colonization with cagA-positive *Helicobacter pylori* strains inversely associated with reflux esophagitis and Barrett's esophagus. Digestion 2000;62:95–9.
50. Newton M, Bryan R, Burnham WR, Kamm MA. Evaluation of *Helicobacter pylori* in reflux oesophagitis and Barrett's oesophagitis. Gut 1997;40:9–13.
51. Vaezi MF, Falk GW, Peek RM et al. CagA-positive strainsof *Helicobacter pylori* may protect against Barrett's esophagus. Amer J Gastroenterol 2000; 95:2206–11.
52. Labenz J, Blum AL, Bayerdorffer E, et al. Curing *Helicobacter pylori* infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442–7.
53. Oberg S, Peters JH, Nigro JJ, et al. *Helicobacter pylori* is not associated with the manifestations of gastroesophageal reflux disease. Arch Surg1999;134: 722–6.
54. Gisbert JP, de Pedro A, Losa C, et al. *Helicobacter pylori* and gastroesophageal reflux disease: lack of influence of infection on twenty-four–hour esophageal pH monitoring and endoscopic findings. J Clin Gastroenterol 2001;32:210–14.
55. Ameriso SF, Fridman EA, Leiguarda RC, Sevlever GE. Detection of *Helicobacter pylori* in human carotid atherosclerotic plaques. Stroke 2001; 32:385–91.
56. Annibale B, Marignani M, Monarca B, et al. Reversal ofiron deficiency anemia after *Helicobacter pylori* eradication in patients with asymptomatic gastritis. Ann Intern Med 1999;131:668–72.

57. Bravos ED, Gilman RH. Accurate diagnosis of *Helicobacter pylori*. Other tests. Gastroenterol Clin North Am2000; 29:925–9.
58. El-Zimaity HM, Graham DY. Evaluation of gastric mucosal biopsy site and number for identification of *Helicobacter pylori* or intestinal metaplasia: role of the Sydney System. Hum Path 1999; 30:72–7.

Access this Article in Online	
	Website: www.ijarbs.com
Quick Response Code	**Subject:** Pharmacy
DOI:10.22192/ijarbs.2016.03.10.004	

How to cite this article:
Debanjan Das, Muhammad Abbas, Md. Akabar, Akriti Nepal, Md. Ariful Islam , Abdullahi Ayuba , Naved Mallick , Awaisullah Ihsen. (2016). A clinical review on the pathology and management "*Helicobacter pylori*" infection. Int. J. Adv. Res. Biol. Sci. 3(10): 18-30.
DOI: http://dx.doi.org/10.22192/ijarbs.2016.03.10.004